General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Share ownership



The information in the following tables relates only to registered shareholders and does not include holders of unregistered shares.

Also, the information provided in the tables below cannot be assumed to be representative of the entire Novartis investor base since nominees and JPMorgan Chase Bank, as ADS depositary, are registered as shareholders for a large number of beneficial owners.

As of December 31, 2013, Novartis had approximately 155 000 registered shareholders.

Registered shareholder types (in %)

Individual shareholders: 11.93% ; Legal entities: 37.18% ; Nominies, fiduciaries and ADS depositary: 50.89%

Registered shares by country (in %)

Switzerland: 40.80%; United States: 47.35% ; France: 0.93% Germany: 3.66% UK: 3.04% Other countries: 4.22%
Stock chart